-

Sema4 Holdings Corp. Stock News: Robbins LLP is Investigating Sema4 Holdings Corp. (SMFR) on Behalf of Shareholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating Sema4 Holdings Corp. (NASDAQ: SMFR) and its officers and directors to determine whether they violated securities laws or breached fiduciary duties in failing to disclose it would reverse a material amount of previously recognized revenue and was experiencing declining sales prices for its Reproductive Health Segment. Sema4 is a health company that uses artificial intelligence to enable personalized medicine.

If you would like more information about Sema4 Holdings Corp's misconduct, click here.

What is this Case About: According to the class action complaint filed against Sema4, on August 15, 2022, the Company announced changes to its research and development leadership team, including that Eric Schadt was stepping down from his roles as President and Chief R&D Officer. The Company also disclosed that it was eliminating approximately 13% of its workforce as part of a series of restructuring and corporate realignments. During the related conference call, Sema4 revealed that it had “reversed $30.1 million of revenue this quarter related to prior periods,” in connection with negotiations with “one of [Sema4’s] larger commercial payors regarding the potential recoupment of payments for Sema4 carrier screening services rendered from 2018 to early 2022.” On this news, Sema4’s stock fell $0.80, or 33.3%, to close at $1.60 per share on August 16, 2022.

Next Steps: If you acquired shares of Sema4 Holdings Corp (SMFR) between March 14, 2022 and August 15, 2022, you have legal options. Contact Robbins LLP for more information about your rights.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Sema4 Holdings Corp settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:SMFR

Release Summary
Sema4 Holdings Corp. failed to disclose it was experiencing declining sales prices for its Reproductive Health Segment.
Release Versions
$Cashtags

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Investor Notice: Robbins LLP Informs Investors of the New Era Energy & Digital, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired New Era Energy & Digital, Inc. (NASDAQ: NUAI) securities between November 6, 2024 and December 29, 2025. New Era Energy, formerly known as New Era Helium (NASDAQ: NEHC), is an oil and natural gas company.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Robbins LLP is...

Investor Notice: Robbins LLP Informs Investors of the Gossamer Bio, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gossamer Bio, Inc. (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026. Gossamer is a clinical stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension (PH) associated with interstitial lung disease. For more information, submit a form, email a...

Investor Notice: Robbins LLP Informs Investors of the Aldeyra Therapeutics, Inc. Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP Is Investigating Allegations that Aldeyra Therapeutics, Inc. (ALDX) Misled Investors Regarding Its Lead Drug Candidate...
Back to Newsroom